Sorafenib with chemo for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of the targeted drug sorafenib and a chemotherapy regimen called FOLFOX4 as a first treatment for advanced or metastatic stomach cancer that cannot be removed by surgery. The goal is to see if this combination is safe and effective for patients who have not had prior chemotherapy or radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are older than 18 years.
- You have been diagnosed with stomach (gastric) adenocarcinoma that is advanced or has spread, and it cannot be removed by surgery.
- You have not had chemotherapy or radiation therapy for your stomach cancer before.
- You have at least one tumor that can be measured on a scan.
- You are able to take care of yourself (ECOG performance status 0 or 1), meaning you are up and about, and you are expected to live at least 3 months.
- You do not have other active cancers, severe bleeding, or serious heart problems, and you are willing to follow the study rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding sorbitol to standard chemotherapy and an immunotherapy drug (tirellizumab) for people with locally advanced stomach cancer. The goal is to see if this combination is safe and helps shrink tumors before surgery.
This trial tests a combination of two drugs, fruquintinib and TAS102, for people with advanced stomach cancer that has stopped responding to at least one prior chemotherapy. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of three drugs — a chemotherapy called irinotecan liposome, a targeted therapy called fruquintinib, and an immunotherapy called sintilimab — for people with advanced stomach cancer whose disease has worsened after their first treatment. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of two targeted drugs (Envafolimab and Fruquintinib) plus chemotherapy given before surgery for certain types of stomach cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of fecal microbiota transplant (FMT), chemotherapy (SOX), and an immunotherapy drug (Sintilimab) as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.